Document is current
Any future updates will be listed below
-
Authors
Li, Yang
Minzhang, Cai
Minghui, Ma
Xinmiao, Huang
Laixin, Liu
Bei, Wang
Weihai, Zhu
Wei, Zhe
Yumei, Guan
Kongnakorn, Thitima
Xiao, Ying
Peng, Siyang
Hughes, David
Dashdorj, Naranjargal
Hach, Thomas
-
Funding
Funding for this research was provided by:
Novartis Pharma AG
- License Information
-
More Information
Article History
Received: 12 October 2019
Accepted: 22 June 2020
First Online: 29 June 2020
Ethics approval and consent to participate
: The study was approved by the ethics committees of the Peking University, School of Public Health, and the study was conducted in accordance with the International Council on Harmonization (ICH, E6) guidelines and Declaration of Helsinki and its subsequent revisions. The data was collected by the Xinjiang CDC and the patient consents were received written before the survey.
: Not applicable.
: YL is a faculty member at Peking University. CM was a graduate student at Peking University. MM, HX, ZW1 and ZW2 are employees of Health and Family Planning Commission of Xinjiang Uygur Autonomous Region, Urumqi, China. LL and GY are employees of Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, China. YX, SP and TK are salaried employees of Evidera, and are not allowed to accept remuneration from any clients for their services. Evidera received funding from Novartis to conduct the study and develop this manuscript. ND is the CEO of Onom foundation, Mongolia. TH, DH, and WB are employees of Novartis Group. Authors have no other competing interests to declare.
